Dr. Reddy’s Laboratories (NYSE:RDY) Sets New 1-Year Low – Time to Sell?

Dr. Reddy’s Laboratories Limited (NYSE:RDY) hit a new 52-week low on Wednesday . The company traded as low as $12.55 and last traded at $12.58, with a volume of 180337 shares changing hands. The stock had previously closed at $12.71.

Analysts Set New Price Targets

Several equities research analysts have weighed in on RDY shares. StockNews.com cut shares of Dr. Reddy’s Laboratories from a “buy” rating to a “hold” rating in a research report on Friday, December 6th. Nomura cut shares of Dr. Reddy’s Laboratories from a “buy” rating to a “neutral” rating in a report on Thursday, December 19th.

Dr. Reddy’s Laboratories Stock Up 0.2 %

The company has a debt-to-equity ratio of 0.02, a current ratio of 1.92 and a quick ratio of 1.38. The company’s 50-day simple moving average is $13.93 and its 200 day simple moving average is $14.84. The firm has a market cap of $10.60 billion, a P/E ratio of 20.21 and a beta of 0.48.

Dr. Reddy’s Laboratories (NYSE:RDY) last announced its quarterly earnings data on Thursday, January 23rd. The company reported $0.20 earnings per share for the quarter, beating analysts’ consensus estimates of $0.19 by $0.01. Dr. Reddy’s Laboratories had a net margin of 17.25% and a return on equity of 17.87%. Research analysts anticipate that Dr. Reddy’s Laboratories Limited will post 0.8 EPS for the current fiscal year.

Institutional Investors Weigh In On Dr. Reddy’s Laboratories

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Robeco Institutional Asset Management B.V. grew its holdings in shares of Dr. Reddy’s Laboratories by 453.8% in the fourth quarter. Robeco Institutional Asset Management B.V. now owns 11,438,908 shares of the company’s stock valued at $180,620,000 after purchasing an additional 9,373,412 shares during the period. Van ECK Associates Corp increased its stake in Dr. Reddy’s Laboratories by 609.4% in the fourth quarter. Van ECK Associates Corp now owns 5,838 shares of the company’s stock valued at $92,000 after purchasing an additional 5,015 shares during the last quarter. World Investment Advisors LLC purchased a new position in Dr. Reddy’s Laboratories in the third quarter valued at approximately $3,459,000. Allspring Global Investments Holdings LLC grew its position in shares of Dr. Reddy’s Laboratories by 400.6% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 534,304 shares of the company’s stock worth $8,373,000 after acquiring an additional 427,573 shares during the last quarter. Finally, Crossmark Global Holdings Inc. grew its position in shares of Dr. Reddy’s Laboratories by 328.3% during the fourth quarter. Crossmark Global Holdings Inc. now owns 12,760 shares of the company’s stock worth $201,000 after acquiring an additional 9,781 shares during the last quarter. Hedge funds and other institutional investors own 3.85% of the company’s stock.

Dr. Reddy’s Laboratories Company Profile

Dr. Reddy’s Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company’s Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.